Compare RPRX & STE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPRX | STE |
|---|---|---|
| Founded | 1996 | 1985 |
| Country | United States | United States |
| Employees | N/A | 3700 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 22.1B |
| IPO Year | 2020 | 2018 |
| Metric | RPRX | STE |
|---|---|---|
| Price | $48.71 | $224.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $50.00 | ★ $275.20 |
| AVG Volume (30 Days) | ★ 2.8M | 567.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.93% | 1.12% |
| EPS Growth | N/A | ★ 62.73 |
| EPS | 1.78 | ★ 5.69 |
| Revenue | $2,378,193,000.00 | ★ $5,459,515,000.00 |
| Revenue This Year | $38.30 | $9.88 |
| Revenue Next Year | $4.80 | $6.32 |
| P/E Ratio | ★ $27.41 | $39.45 |
| Revenue Growth | 5.06 | ★ 6.24 |
| 52 Week Low | $31.58 | $209.98 |
| 52 Week High | $49.06 | $269.44 |
| Indicator | RPRX | STE |
|---|---|---|
| Relative Strength Index (RSI) | 63.84 | 48.25 |
| Support Level | $35.32 | $221.44 |
| Resistance Level | $49.06 | $226.33 |
| Average True Range (ATR) | 0.93 | 4.05 |
| MACD | 0.07 | 1.58 |
| Stochastic Oscillator | 91.90 | 82.12 |
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.